# An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis

> **NCT02189252** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 30 (actual)

## Conditions studied

- Severe Hypertriglyceridemia

## Interventions

- **DRUG:** Epanova
- **DRUG:** Lovaza

## Key facts

- **NCT ID:** NCT02189252
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2016-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02189252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02189252, "An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02189252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*